Paliperidone extended release (ER)

DRUG3 trials

Sponsors

Janssen Research & Development, LLC, Janssen-Cilag Farmaceutica Ltda., Janssen-Cilag Ltd.,Thailand

Conditions

Schizophrenia

Phase 3

An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia

CompletedNCT01009047

Janssen Research & Development, LLCSchizophrenia

Start: 2009-12-31End: 2012-06-30Updated: 2013-06-21

Phase 4

A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone

CompletedNCT01010776

Janssen-Cilag Farmaceutica Ltda.Schizophrenia

Start: 2008-02-29End: 2009-12-31Updated: 2013-11-20

Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants

CompletedNCT01387542

Janssen-Cilag Ltd.,ThailandSchizophrenia

Start: 2009-08-31End: 2010-09-30Updated: 2013-03-05

Related Papers

Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.

2014-11-2526 citations

Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.

2014-07-1110 citations

Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.

2013-12-168 citations